Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORMOZIDE vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Prazosin is extensively metabolized in the liver via demethylation and conjugation. Polythiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Approximately 85-90% bound to serum albumin and alpha-1 acid glycoprotein.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
0.5-0.8 L/kg, indicating moderate distribution into extravascular tissues. Clinically, this suggests loading doses may be needed for rapid effect.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability is 40-60% due to first-pass metabolism. Intravenous bioavailability is 100%.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 5 mg once daily. GFR 15-29 m L/min: 2.5 mg once daily. GFR <15 m L/min: Not recommended.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not approved for pediatric use. Safety and efficacy not established.
Not established; avoid use in children.
Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity and renal impairment risk.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Orthostatic hypotension and syncope, especially with first dose,Sodium and fluid depletion,Electrolyte imbalances (hypokalemia, hyponatremia),Renal impairment,Hepatic impairment,Possible increased risk of adverse effects in patients on beta-blockers or digitalis
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to prazosin, polythiazide, or sulfonamides,Anuria,Hepatic coma or precoma,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, avocados) and potassium-containing salt substitutes. Grapefruit may increase drug levels; avoid grapefruit juice.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: Increased risk of fetal renal dysfunction, oligohydramnios, and neonatal complications such as hypotension, hyperkalemia, and skull hypoplasia.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
NORMOZIDE is excreted in breast milk. M/P ratio: approximately 0.8. Avoid breastfeeding due to potential risk of hypotension and electrolyte disturbances in the infant.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
NORMOZIDE is not recommended in pregnancy. If used inadvertently, dose adjustments are not indicated; immediate discontinuation advised. Plasma levels may decrease in pregnancy due to increased volume of distribution, but no safe dosage can be established.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Monitor serum potassium and renal function before and during therapy due to risk of hyperkalemia. Avoid use with potassium supplements or salt substitutes containing potassium. Adjust dose in elderly and patients with hepatic impairment. Caution in patients with severe renal impairment (Cr Cl <30 m L/min).
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed, usually once daily.,Avoid potassium-rich foods and salt substitutes.,Report symptoms of hyperkalemia: muscle weakness, fatigue, palpitations.,May cause dizziness; avoid driving until effect known.,Do not stop abruptly without consulting prescriber.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORMOZIDE vs ALDORIL 25, answered by our medical review team.
NORMOZIDE is a Antihypertensive Combination that works by Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORMOZIDE and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORMOZIDE is: Oral: 10 mg once daily. Maximum dose: 20 mg once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORMOZIDE and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORMOZIDE is classified as Category C. NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Seco. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.